BioStock: Go-ahead for Lipum’s study – CMO comments

Lipum’s clinical trial application was recently approved by the regulatory authorities in the Netherlands, which means that the clinical phase I study with SOL-116 can be initiated. This marks an important milestone where Lipum is transitioning from preclinical to clinical phase, says the company’s CMO Helena Bergström in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/10/go-ahead-for-lipums-study-cmo-comments/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/